Penzberg, Germany

Sarah Liedke

USPTO Granted Patents = 1 

Average Co-Inventor Count = 3.0

ph-index = 1


Company Filing History:


Years Active: 2025

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovations of Sarah Liedke

Introduction

Sarah Liedke is a prominent inventor based in Penzberg, Germany. She has made significant contributions to the field of medical diagnostics, particularly in the development of antibodies for cardiac health. Her work is recognized for its potential to improve diagnostic accuracy and patient outcomes.

Latest Patents

One of Sarah Liedke's notable patents is related to anti-troponin T antibodies. This invention focuses on improved variant monoclonal antibodies that bind to cardiac troponin T. These antibodies exhibit a better affinity than the previously established monoclonal antibody 12.1A11.11-7. The patent is a significant advancement in cardiac diagnostics, as it enhances the detection of heart-related conditions.

Career Highlights

Sarah Liedke is currently employed at Roche Diagnostics Operations, Inc., a leading company in the field of medical diagnostics. Her role involves research and development, where she applies her expertise to create innovative solutions for healthcare challenges. With her dedication and skill, she has established herself as a valuable asset to her team.

Collaborations

Sarah has collaborated with notable colleagues, including Frank Kroner and Michael Schraeml. These partnerships have fostered a collaborative environment that encourages innovation and the sharing of ideas.

Conclusion

In summary, Sarah Liedke is an accomplished inventor whose work in developing anti-troponin T antibodies has the potential to revolutionize cardiac diagnostics. Her contributions to Roche Diagnostics Operations, Inc. and her collaborations with esteemed colleagues highlight her commitment to advancing medical technology.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…